Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Mark A. Preston

Urology
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Advanced in WT1-Related Wilms Tumor Syndromes
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Preston is an Urologist in Boston, Massachusetts. Dr. Preston is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Prostate Cancer, Cystectomy, and Prostatectomy. Dr. Preston is currently accepting new patients.

His clinical research consists of co-authoring 138 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Urology
Licenses
Urology in MA
Hospital Affiliations
Newton-Wellesley Hospital
Massachusetts General Hospital
Brigham And Women's Hospital
Brigham And Women's Faulkner Hospital
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215
Other Locations
BRIGHAM AND WOMENS PHYSICIANS ORGANIZATION INC
75 Francis St, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
Sexual Function in Women After Radical Cystectomy
Sexual Function in Women After Radical Cystectomy
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Other
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
A Phase 3, Multi-Center, Open-Label Study to Assess the Diagnostic Performance and Clinical Impact of 18F-DCFPyL PET/CT Imaging Results in Men With Suspected Recurrence of Prostate Cancer
Enrollment Status: Completed
Publish Date: June 14, 2021
Intervention Type: Diagnostic test, Drug
Study Phase: Phase 3
View 3 Less Clinical Trials

138 Total Publications

Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients.
Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients.
Journal: Future oncology (London, England)
Published: April 01, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Steven L. Chang
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Steven L. Chang
Urology

Brigham And Womens Physicians Organization Inc

45 Francis St, 
Boston, MA 
 (0.2 miles away)
617-732-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Steven Chang is an Urologist in Boston, Massachusetts. Dr. Chang is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Ureterocele, WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Reconstructive Urology Surgery, and Nephrectomy. Dr. Chang is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Andrew A. Wagner
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Andrew A. Wagner
Urology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

200 Boylston St, 
Chestnut Hill, MA 
 (3.7 miles away)
781-983-9088
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Andrew Wagner is an Urologist in Chestnut Hill, Massachusetts. Dr. Wagner is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, Nephrectomy, and Cystectomy. Dr. Wagner is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Douglas M. Dahl
Urology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Douglas M. Dahl
Urology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Douglas Dahl is an Urologist in Boston, Massachusetts. Dr. Dahl is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Prostatectomy, and Nephrectomy. Dr. Dahl is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Preston's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile